Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma.
نویسندگان
چکیده
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.
منابع مشابه
Primary Hepatic Diffuse Large B-Cell Lymphoma in a Patient with Scleroderma
Primary Hepatic Lymphoma (PHL) is rare and possibly associated with viral hepatitis and autoimmune diseases. Scleroderma could exceptionally be complicated by lymphoma. We describe PHL occurring in a 52-year-old female suffering scleroderma for eight years, with no history of cytotoxic or high-dose glucocorticoid therapy. CT scan, performed to work-up abdominal discomfort, constipation, and ...
متن کاملABC of D's in the folate transporter.
However, the strategy of antiviral therapy after completion of chemotherapy in the HCV-positive patient is attractive and was associated with improved outcomes in one small retrospective study. 11 The optimal timing of HCV antiviral therapy in aggressive lymphoma will require prospective study, and the results from Ennishi et al suggest that further efforts to prevent progressive liver failure ...
متن کاملBCL2 Family Related Genes Expression and Chemotherapy Response in Diffuse Large B-Cell Lymphoma
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens we...
متن کاملRituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma.
Rituximab treatment may cause or exacerbate Kaposi's sarcoma (KS) in patients with human immunodeficiency virus (HIV)-associated multicentric Castleman's disease. Despite the widespread use of rituximab, rituximab-induced KS has not yet been reported in HIV-negative patients with diffuse large B cell lymphoma (DLBCL). We herein report a case of KS that developed after undergoing rituximab-conta...
متن کاملClinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Clinical outcome of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis C virus (HCV) infection in the rituximab era remains unclear. The aim of the present study was to compare the clinical outcome, treatment response and hepatotoxicity in DLBCL patients who received rituximab containing immunochemotherapy that had HCV infection and tho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of hepatology
دوره 14 5 شماره
صفحات -
تاریخ انتشار 2015